专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO9404565A2 IPNV VACCINE 审中-公开
标题翻译： IPNV疫苗
公开(公告)号：WO9404565A2
公开(公告)日：1994-03-03
申请号：PCT/GB9301812
申请日：1993-08-25
申请人： PROTEUS HOUSE , FISHLEIGH ROBERT VINCENT , GREANEY PAUL JOHN , ROBSON BARRY , SHAKESPEARE ANN PATRICIA
发明人： FISHLEIGH ROBERT VINCENT , GREANEY PAUL JOHN , ROBSON BARRY , SHAKESPEARE ANN PATRICIA
IPC分类号： A61K38/00 , A61K39/00 , C07K7/02 , C07K14/08 , C07K16/10 , C07K16/42 , C12N15/40 , C07K7/08 , A61K37/02 , A61K39/12 , A61K39/42 , C07K7/10 , G01N33/53
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C07K7/02 , C07K16/10 , C07K16/42 , C12N2720/10022
摘要： The invention provides a synthetic polypeptide having at least one antigenic property of at least one strain of infectious pancreatic necrosis virus, said polypeptide consisting substantially of an amino acid sequence selected from formulae (I) to (IX): formula (I) (which contains Seq. ID No: 1) X-Thr-Thr-Asn-Pro-Gln-Asp-Lys-Val-Asn-Asn-Gln-Y; formula (II) (which contains Seq. ID Nos: 2 or 3) X-Thr-Asp-Phe-R1-Ser-Asp-Leu-Pro-Thr-Ser-Lys-Ala-Trp-Gly-Y; formula (III) (which contains Seq. ID No: 4) X-Pro-Thr-Ser-Lys-Ala-Trp-Gly-Trp-Arg-Asp-Y;fFormula (IV) (which contains Seq. ID No: 5) X-Thr-Lys-Tyr-Gly-Lys-Tyr-Asp-Pro-Glu-Gly-Y; formula (V) (which contains Seq. ID No: 6) X-Leu-Glu-Val-Ser-Glu-Ser-Gly-Ser-Gly-Y; formula (VI) (which contains Seq. ID Nos: 7 or 8) X-Gln-Glu-Thr-Ser-Ser-Tyr-R2-Leu-Glu-Val-Ser-Glu-Ser-Gly-Y; formula (VII) (which contains Seq. ID Nos: 9 or 10) X-Ser-Arg-Phe-Thr-Pro-Ser-Gly-Asp-R3-Y; and formula (VIII) (which contains Seq. ID Nos: 11 or 12) X-Pro-His-Gln-Glu-Pro-Ala-Pro-R4-Phe-Tyr-Y; formula (IX) (which contains Seq. ID Nos: 13, 14, 15 or 16) X-Pro-Gln-Gly-R5-Gln-Ser-Met-Asn-Gly-Ala-R6-Y, wherein R1 is Ser or Thr; R2 is Thr or Asn; R3 is Asp-Gly or Asn-Ala; R4 is Asp-Asp or Glu-Glu-; R5 is Pro or Leu; R6 is Arg or Lys; and X and Y may each independently be absent or independently be one or more amino acid residues, useful for the treatment of IPNV infection in fish.
摘要翻译：本发明提供了具有至少一种感染性胰脏坏死病毒株的至少一种抗原性的合成多肽，所述多肽基本上由选自式（I）至（IX）的氨基酸序列组成：所述式（I） Seq.ID No：1）X-Thr-Thr-Asn-Pro-Gln-Asp-Lys-Val-Asn-Asn-Gln-Y; （II）（其含有Seq.ID Nos：2或3）X-Thr-Asp-Phe-R1-Ser-Asp-Leu-Pro-Thr-Ser-Lys-Ala-Trp-Gly-Y; （III）（其含有Seq.ID No：4）X-Pro-Thr-Ser-Lys-Ala-Trp-Gly-Trp-Arg-Asp-Y; f式（IV） 5）X-Thr-Lys-Tyr-Gly-Lys-Tyr-Asp-Pro-Glu-Gly-Y; （V）（其含有Seq.ID No：6）X-Leu-Glu-Val-Ser-Glu-Ser-Gly-Ser-Gly-Y; （VI）（其含有Seq.ID Nos：7或8）X-Gln-Glu-Thr-Ser-Ser-Tyr-R2-Leu-Glu-Val-Ser-Glu-Ser-Gly-Y; （VII）（其含有Seq.ID Nos：9或10）X-Ser-Arg-Phe-Thr-Pro-Ser-Gly-Asp-R3-Y; 和式（VIII）（其含有Seq.ID Nos：11或12）X-Pro-His-Gln-Glu-Pro-Ala-Pro-R4-Phe-Tyr-Y; （IX）（其含有Seq.ID Nos：13,14,15或16）X-Pro-Gln-Gly-R5-Gln-Ser-Met-Asn-Gly-Ala-R6-Y，其中R1是Ser 或Thr; R2是Thr或Asn; R3是Asp-Gly或Asn-Ala; R4是Asp-Asp或Glu-Glu-; R5是Pro或Leu; R6是Arg或Lys; 并且X和Y可以各自独立地不存在或独立地为一个或多个氨基酸残基，可用于治疗鱼中的IPNV感染。

2. 发明申请

WO9323550A3 ACTIVATION OF OLIGOMERIZING RECEPTORS BY USING FUSED RECEPTOR LIGANDS 审中-公开
标题翻译：通过使用融合受体配体激活受体的低聚物
公开(公告)号：WO9323550A3
公开(公告)日：1994-03-03
申请号：PCT/US9304717
申请日：1993-05-17
申请人： GENENTECH INC
发明人： GODOWSKI PAUL J
IPC分类号： C12N15/09 , A61K47/48 , C07K1/113 , C07K14/475 , C07K14/48 , C07K14/485 , C07K14/495 , C07K14/505 , C07K14/52 , C07K14/53 , C07K14/535 , C07K14/54 , C07K14/545 , C07K14/55 , C07K14/575 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/71 , C07K14/715 , C07K16/00 , C07K19/00 , C12N15/62 , C07K7/10
CPC分类号： C07K14/715 , A61K47/62 , A61K47/6811 , A61K47/6877 , C07K14/4753 , C07K14/71 , C07K16/00 , C07K2317/74 , C07K2319/036 , C07K2319/30 , C07K2319/32 , C07K2319/50
摘要： The invention concerns a method for activating receptors selected from receptor tyrosine kinases, cytokine receptors and members of the nerve growth factor receptor superfamily. A conjugate comprising the direct fusion of at least two ligands capable of binding to the receptor(s) to be activated is contacted with the receptors, whereby the ligands bind their respective receptors inducing receptor oligomerization.

3. 发明申请

WO9211370A3 POLYPEPTIDES DERIVED FROM PROTEINS OF THE HEPATITIS C VIRUS 审中-公开
标题翻译：来源于丙型肝炎病毒蛋白的多肽
公开(公告)号：WO9211370A3
公开(公告)日：1992-10-29
申请号：PCT/DE9101020
申请日：1991-12-20
申请人： BOEHRINGER MANNHEIM GMBH
发明人： FUCHS KLAUS , MOTZ MANFRED , ROGGENDORF MICHAEL , SOUTSCHEK ERWIN
IPC分类号： A61K39/29 , A61K39/00 , A61P31/12 , C07H21/04 , C07K14/00 , C07K14/02 , C07K14/10 , C07K14/18 , C07K14/705 , C07K19/00 , C12N1/21 , C12N15/09 , C12N15/51 , C12P21/02 , C12Q1/68 , C12R1/19 , G01N33/53 , G01N33/576 , C07K7/10 , C07K13/00
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222
摘要： Disclosed is the cloning and sequencing of various polypeptides from the genome of the hepatitis C virus. The polypeptides are prepared as non-fusion proteins in high yields. The polypeptide originating in the core protein is soluble under physiological conditions. Since the polypeptides contain no foreign protein fractions, they are particularly suitable for use in test kits and as vaccines.
摘要翻译：公开了来自丙型肝炎病毒基因组的各种多肽的克隆和测序。多肽以高产率制备为非融合蛋白。源于核心蛋白的多肽在生理条件下是可溶的。由于多肽不含外源蛋白质级分，因此它们特别适用于测试试剂盒和疫苗。

4. 发明申请

WO9012807A3 PURIFIED, HIGHLY SPECIFIC ANTIBODIES AGAINST GENE PRODUCTS INCLUDING RETINOBLASTOMA AND METHOD 审中-公开
标题翻译：纯化的抗体基因产物的高特异性抗体包括雷公藤内酯和方法
公开(公告)号：WO9012807A3
公开(公告)日：1991-01-10
申请号：PCT/US9002017
申请日：1990-04-13
申请人： BAYLOR COLLEGE MEDICINE
发明人： XU HONG-JI , BENEDICT WILLIAM F , HU SHI-XUE
IPC分类号： A61K39/00 , A61K39/395 , C07K7/00 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/47 , C07K16/00 , C07K16/32 , C07K17/00 , C07K17/02 , C07K19/00 , C12P21/08 , G01N33/53 , G01N33/531 , G01N33/574 , C07K7/10
CPC分类号： C07K14/4736 , C07K16/18
摘要： A method of identifying epitopes to gene products, specifically the human retinoblastoma (Rb) gene and the corresponding antigenic polypeptides. The amino acid sequence has a combination of low solubility and high hydrophilicity. Highly specific high-affinity anti-Rb-IgGs have been purified using the techniques of this invention. The anti-Rb-IgGs have been used to immuno-precipitate and produce Western Blot patterns associated with normal and abnormal Rb proteins. The method and products of this invention can be used in various diagnostic procedures.

5. 发明申请

WO8804666A3 LUNG CYTOTOXIC PEPTIDES 审中-公开
标题翻译：肺癌细胞毒素
公开(公告)号：WO8804666A3
公开(公告)日：1988-08-11
申请号：PCT/US8703399
申请日：1987-12-23
申请人： IVAX LAB INC
发明人： SOLOMON SAMUEL
IPC分类号： A61K38/00 , C07K14/47 , C07K7/10 , A61K37/02
CPC分类号： C07K14/4703 , A61K38/00
摘要： A method of reducing lung tumor population in a cancer inflicted patient which comprises contacting lung carcinoma cells in said patient with a peptide selected from the group consisting of Cys-Try-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Try-Gly-Thr-Cys-Ile-Try-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys or Ala-Cys-Try-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Try-Gly-Thr-Cys-Ile-Try-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys. Anticarcinoma compositions are disclosed including an isotonic solution and an aerosol spray, each containing an effective amount of said peptide. Also disclosed is method of producing substantially pure peptide mixture of each of said peptides. Compositions including the compound Cys-Try-Cys-Arg-Ile-Pro-Ala-Cys-Ile-Ala-Gly-Glu-Arg-Arg-Try-Gly-Thr-Cys-Ile-Try-Gln-Gly-Arg-Leu-Trp-Ala-Phe-Cys-Cys are provided.

6. 发明申请

WO9315112A3 COMPOUNDS AND METHODS FOR INHIBITING (BETA)-PROTEIN FUNCTION 审中-公开
标题翻译：化合物和抑制（BETA） - 蛋白质功能的方法
公开(公告)号：WO9315112A3
公开(公告)日：1993-09-02
申请号：PCT/US9300325
申请日：1993-01-13
申请人： HARVARD COLLEGE
发明人： POTTER HUNTINGTON , KAYYALI USAMAH
IPC分类号： A61K38/55 , A61K31/185 , A61K31/337 , A61K31/365 , A61K38/00 , A61K45/00 , A61P25/28 , C07D305/12 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/47 , C07K14/81 , C12N9/00 , C12N9/50 , C12Q1/37 , C12Q1/44 , C12Q1/46 , G01N33/68 , A61K31/155 , A61K31/335 , A61K37/02 , C07K7/10 , C12Q1/34
CPC分类号： C07K14/8121 , A61K38/00 , C07K14/4711 , C12Q1/37 , C12Q1/44 , G01N33/6896 , G01N2333/4709 , G01N2333/8125 , G01N2500/20 , G01N2800/2821
摘要： A method of interfering with the interaction and/or function of α1-antichymotrypsin (ACT) and Alzheimer's β-protein and, as a result, reducing the adverse side effects associated with formation of a complex comprising the two or with activity of the complex components. In one embodiment, the subject invention relates to methods of interfering with formation of a specific complex between ACT and β-protein. In another embodiment, the present invention relates to methods of inhibiting the function of the components of the ACT-β-protein complex. In particular, it relates to methods of inhibiting the function of β-protein, particularly enzymatic activity, such as esterase (cholinesterase) or protease activity. Both methods are useful in treating or preventing the effects of complex formation or of the enzymatic activity of the β-protein and, thus, provide a potential method of treating or preventing Alzheimer's disease, Down's syndrome or normal aging. Compositions and compounds useful in the method are also the subject of this invention.

7. 发明申请

WO9217493A3 Peptides and mixtures thereof for detecting antibodies to hepatitus C virus (HCV) 审中-公开
标题翻译：肽及其混合物用于检测C型肝炎病毒（HCV）的抗体
公开(公告)号：WO9217493A3
公开(公告)日：1992-12-10
申请号：PCT/CA9200137
申请日：1992-04-03
申请人： IAF BIOCHEM INT
发明人： LACROIX MARTIAL
IPC分类号： A61K39/245 , A61K39/00 , A61K39/29 , A61K39/295 , A61K39/39 , A61P31/12 , A61P31/14 , C07K7/08 , C07K14/00 , C07K14/18 , C07K16/00 , C07K16/10 , C12N15/02 , C12P21/08 , G01N33/53 , G01N33/576 , G01N33/577 , C07K7/10
CPC分类号： C07K14/005 , A61K39/00 , C07K16/109 , C12N2770/24222
摘要： This invention relates to novel peptides from the hepatitis C virus polyprotein amino acid regions 1-81, 101-127 and 210-231 and mixtures thereof useful for detecting HCV infections. These peptides are also useful as active ingredients in vaccines against HCV infection.

8. 发明申请

WO9119736A3 CANCER-ASSOCIATED SCM-RECOGNITION FACTOR, PREPARATION AND METHOD OF USE 审中-公开
标题翻译：癌症相关SCM识别因子，准备和使用方法
公开(公告)号：WO9119736A3
公开(公告)日：1992-02-20
申请号：PCT/US9104334
申请日：1991-06-18
申请人： CERCEK BORIS , CERCEK LEA
发明人： CERCEK BORIS , CERCEK LEA
IPC分类号： A61K38/00 , A61K35/16 , A61K39/395 , A61K47/48 , A61K49/00 , A61P35/00 , C07K1/20 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/47 , C07K14/585 , C07K14/81 , C07K16/00 , C07K16/18 , C12N1/21 , C12N15/12 , C12P21/08 , G01N33/50 , G01N33/53 , G01N33/574 , A61K37/02 , C07K7/10
CPC分类号： A61K35/16 , A61K38/00 , A61K47/6845 , C07K7/08 , C07K14/4745 , C07K14/585 , C07K16/18 , G01N33/5011 , G01N33/5091 , Y10S436/811 , Y10S436/813
摘要： A cancer recognition factor (SCM factor) useful in the performance of the structuredness of the cytoplasmic matrix (SCM) test has been isolated, purified to substantial homogeneity, and characterized, and methods for its use have been described. The factor is a peptide of at least 9 amino acid residues including a core sequence of 9 amino acid residues having an amphipathicity profile substantially equivalent to that of the sequence F-L-M-I-D-Q-N-T-K and produces at least a 10 percent decrease in the intracellular fluorescence polarization value of SCM-responding lymphocytes from donors afflicted with cancer. A synthetic SCM factor representing a consensus sequence of M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K is fully active. Antibodies specific for SCM factor are useful in immunoassays that can detect the factor, including detection in cancer cells grown in vitro. The SCM factor is useful for screening of blood samples and other body fluids or cell aspirates for the presence of malignancy in the donor. The multiple action spectrum of the SCM factor including cancer proliferation and invasion promotion, as well as inhibition of the host's immune defense mechanisms and synthesis of SCM factor by cancer cells, represents a novel target for cancer management. Methods for reducing in vivo activity of the SCM factor, such as dialysis or antibody neutralization, can also be useful in the management of cancer.

9. 发明申请

WO9115512A3 HIV ENVELOPE POLYPEPTIDES 审中-公开
标题翻译：艾滋病毒包膜多糖
公开(公告)号：WO9115512A3
公开(公告)日：1991-12-12
申请号：PCT/US9102166
申请日：1991-04-01
申请人： GENENTECH INC
发明人： GREGORY TIMOTHY J , LEONARD CORDELIA K , SPELLMAN MICHAEL W
IPC分类号： A61K38/00 , A61K39/00 , A61K39/21 , A61K39/395 , A61P31/12 , C07K7/08 , C07K14/00 , C07K14/16 , C07K16/00 , C12N15/09 , C12P21/02 , C12P21/06 , C12P21/08 , C12R1/91 , C07K7/64 , C07K7/10 , C07K15/28
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2740/16122
摘要： Novel isolated physiologically active polypeptides are provided, as well as antibodies directed against the isolated polypeptides. Methods for the preparation and pharmaceutical use of the polypeptides and antibodies are also provided.

10. 发明申请

WO9003435A3 NUCLEIC ACID CODING FOR THE HUMAN ANGIOTENSINE CONVERSION ENZYME (ACE), AND ITS APPLICATIONS PARTICULARLY FOR THE (IN VITRO) DIAGNOSIS OF HIGH BLOOD PRESSURE 审中-公开
标题翻译：人类血管紧张素转换酶（ACE）的核酸编码及其特别应用于（血管内）高血压检测
公开(公告)号：WO9003435A3
公开(公告)日：1990-05-31
申请号：PCT/FR8900496
申请日：1989-09-27
申请人： INST NAT SANTE RECH MED
发明人： SOUBRIER FLORENT , ALHENC-GELAS FRANCOIS , HUBERT CHRISTINE , CORVOL PIERRE
IPC分类号： C12N15/09 , A61K38/00 , C07K16/40 , C12N7/00 , C12N9/48 , C12N9/64 , C12N15/16 , C12N15/57 , C12P21/08 , C12Q1/68 , A61K37/02 , C07K7/10 , C12P21/02 , C12Q1/37 , G01N33/68
CPC分类号： C12Q1/6827 , A61K38/00 , C07K16/40 , C12N9/48 , C12Q1/683 , C12Q1/6883 , C12Q2600/156
摘要： The invention relates to the cloning and sequencing of nucleic acid coding for human ACE as well as to the determination of the peptidic chain corresponding to ACE and active peptidic fragments derived therefrom. The invention also relates to the utilization of the above-mentioned polypeptides for implementing methods for in vitro diagnosis of high blood pressure, for the conceptual study of new inhibitors of ACE. The invention also relates to the use of nucleotidic probes of the invention for the in vitro detection of polymorphisms of the gene coding for ACE.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式